KIA
ALNY icon

Knollwood Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Knollwood Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,059
Closed -$1.85M – 321
2025
Q3 		$1.85M Sell
4,059
-1,296
-24% -$528K 0.17% 128
2025
Q2 		$1.75M Hold
5,355
– – 0.17% 134
2025
Q1 		$1.45M Hold
5,355
– – 0.16% 146
2024
Q4 		$1.26M Hold
5,355
– – 0.13% 160
2024
Q3 		$1.47M Hold
5,355
– – 0.16% 155
2024
Q2 		$1.3M Buy
+5,355
New +$845K 0.14% 158

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Knollwood Investment Advisory's ALNY Position: Q4 2025 in Review

Knollwood Investment Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,059 shares — an estimated $1.85M sold.

Knollwood Investment Advisory first reported a position in ALNY in Q2 2024 and held it in 6 quarters. The position peaked at $1.85M in Q3 2025. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Knollwood Investment Advisory reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Knollwood Investment Advisory sold 4,059 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $1.85M.
  • Knollwood Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Knollwood Investment Advisory's Alnylam Pharmaceuticals position peaked at $1.85M in Q3 2025.
  • 849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Knollwood Investment Advisory's 13F filing for Q4 2025, filed 13 Feb 2026.